Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    6
    ...
ATC Name B/G Ingredients Dosage Form Price
R05 EXALL FORTE G Chlorpheniramine maleate - 2.5mg, Guaifenesin - 100mg, Acetaminophen - 100mg, Diprophylline - 25mg Syrup 501,701 L.L
B03AB ENRICH N G Iron trivalent (hydroxide polymaltose complex) - 156.25mg/5ml Syrup 279,519 L.L
A07BA51 EUCARBON B Rhubarbe - 25mg, Sulfur - 50mg, Senna - 105mg, Vegetal charcoal - 180mg Tablet 795,555 L.L
N02BE51 EXTRA STRENGTH HEADACHE RELIEF G Acetaminophen - 250mg, Acetylsalicylic acid - 250mg, Caffeine - 65mg Tablet 353,431 L.L
C09CA09 EDARBI B Azilsartan medoxomil - 40mg 40mg Tablet 1,846,440 L.L
C09CA09 EDARBI B Azilsartan medoxomil - 80mg 80mg Tablet 2,023,827 L.L
C10AX09 EZETROL B Ezetimibe - 10mg 10mg Tablet 3,680,849 L.L
C10AX09 EZETIMIBE BIOGARAN G Ezetimibe - 10mg 10mg Tablet 1,894,818 L.L
C10AX09 EZETRALEX G Ezetimibe - 10mg 10mg Tablet 972,686 L.L
G03AD02 ELLAONE B Ulipristal acetate - 30mg 30mg Tablet 2,276,469 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 2.5mg 2.5mg Tablet L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 5mg 5mg Tablet L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 10mg 10mg Tablet L.L
G03DA04 ENDOMETRIN B Progesterone - 100mg 100mg Tablet 2,776,379 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 5mg 5mg Tablet L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 10mg 10mg Tablet L.L
G03XC01 EVA TABLET G Raloxifene HCl - 60mg 60mg Tablet 1,354,081 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 5mg 5mg Tablet 89,386,347 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 5mg 5mg Tablet 66,619,921 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 10mg 10mg Tablet 124,701,632 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 10mg 10mg Tablet 83,550,282 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 2.5mg 2.5mg Tablet 52,290,378 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 2.5mg 2.5mg Tablet 52,634,673 L.L
C09BB06 ENEAS G Enalapril maleate - 10mg, Nitrendipine - 20mg Tablet 2,009,045 L.L
C03AA03 ESIDREX B Hydrochlorothiazide - 25mg 25mg Tablet 380,115 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
J05AF10 ENTECAVIR BIOGARAN G Entecavir - 1mg 1mg Tablet, coated 19,080,319 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 1mg 1mg Tablet, coated 18,701,506 L.L
J05AF10 ENTECAVIR BIOGARAN G Entecavir - 0.5mg 0.5mg Tablet, coated 19,080,319 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 1mg 1mg Tablet, coated L.L
    ...
    6
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025